By: IPP Bureau
Last updated : May 15, 2026 7:49 am
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Senores Pharmaceuticals Limited reported strong financial and operational performance for Q4 and FY26, driven by growth across regulated markets, emerging markets, and branded generics businesses.
For Q4 FY26, the company reported total income of Rs. 190 crore, registering a 58% year-on-year increase. EBITDA rose 144% YoY to Rs. 62 crore, while profit after tax (PAT) increased 105% YoY to Rs. 37 crore.
For the full year FY26, consolidated total income stood at Rs. 664 crore, reflecting 62% growth over the previous year. EBITDA increased 96% YoY to Rs. 200 crore, while PAT rose 108% to Rs. 122 crore. Operating cash flow for the year reached Rs. 75 crore, supported by improved EBITDA-to-cash flow conversion.
The regulated markets business remained the company’s primary growth driver. Q4 FY26 revenue from regulated markets rose 83% YoY to Rs. 117.8 crore, while FY26 revenue increased 74.6% YoY to Rs. 427.4 crore.
The company currently has 51 approved ANDAs covering 151 strengths, compared to 26 approved ANDAs as of March 2025. More than 30 approved ANDAs remain to be commercialized, while 27 ANDAs involving over 65 strengths are under development.
The emerging markets business also delivered steady growth, with Q4 FY26 revenue increasing 25.8% YoY to Rs. 45.9 crore and FY26 revenue rising 19.7% to Rs. 145 crore. EBITDA margins for the segment stood at approximately 12%.
The India-focused branded generics business recorded significant expansion. Q4 FY26 revenue grew 132.4% YoY to Rs. 9.4 crore, while FY26 revenue surged nearly 385% YoY to Rs. 40 crore, supported by approvals from multi-specialty and specialty hospitals.
Commenting on the performance, Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, said the company delivered robust growth despite a challenging operating environment and highlighted the expansion of the ANDA portfolio, strengthening manufacturing capabilities, and enhanced U.S. commercialization infrastructure as key drivers for long-term growth.